| Title |
Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity
|
|---|---|
| Published in |
Drug Design, Development and Therapy, March 2016
|
| DOI | 10.2147/dddt.s80804 |
| Pubmed ID | |
| Authors |
Michelle Kaku, David M Simpson |
| Abstract |
Poststroke spasticity affects up to one-half of stroke patients and has debilitating effects, contributing to diminished activities of daily living, quality of life, pain, and functional impairments. Botulinum toxin (BoNT) is proven to be safe and effective in the treatment of focal poststroke spasticity. The aim of this review is to highlight BoNT and its potential in the treatment of upper and lower limb poststroke spasticity. We review evidence for the efficacy of BoNT type A and B formulations and address considerations of optimal injection technique, patient and caregiver satisfaction, and potential adverse effects of BoNT. |
Mendeley readers
The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 94 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 17% |
| Student > Master | 11 | 12% |
| Student > Doctoral Student | 8 | 9% |
| Student > Postgraduate | 7 | 7% |
| Other | 6 | 6% |
| Other | 22 | 23% |
| Unknown | 24 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 31% |
| Nursing and Health Professions | 14 | 15% |
| Neuroscience | 5 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Sports and Recreations | 3 | 3% |
| Other | 11 | 12% |
| Unknown | 29 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2016.
All research outputs
#22,935,114
of 25,576,275 outputs
Outputs from Drug Design, Development and Therapy
#1,760
of 2,274 outputs
Outputs of similar age
#269,603
of 313,042 outputs
Outputs of similar age from Drug Design, Development and Therapy
#66
of 83 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 313,042 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.